Statistics
Total Visits
| Views | |
|---|---|
| A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16) | 99 |
Total Visits Per Month
| March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | August 2024 | September 2024 | |
|---|---|---|---|---|---|---|---|
| A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16) | 0 | 0 | 3 | 1 | 1 | 4 | 5 |
Top country views
| Views | |
|---|---|
| Poland | 52 |
| United States | 29 |
| China | 4 |
| Japan | 4 |
| Sweden | 3 |
| France | 2 |
| Ireland | 2 |
| Argentina | 1 |
| Australia | 1 |
| India | 1 |
Top cities views
| Views | |
|---|---|
| Warsaw | 52 |
| San Ramon | 6 |
| Ann Arbor | 5 |
| Boardman | 5 |
| Beijing | 4 |
| Tokyo | 3 |
| Dublin | 2 |
| Stockholm | 2 |
| Des Moines | 1 |
| Fairfield | 1 |